0001123292-24-000200.txt : 20240724 0001123292-24-000200.hdr.sgml : 20240724 20240723174355 ACCESSION NUMBER: 0001123292-24-000200 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20240724 DATE AS OF CHANGE: 20240723 EFFECTIVENESS DATE: 20240724 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Phio Pharmaceuticals Corp. CENTRAL INDEX KEY: 0001533040 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-519563 FILM NUMBER: 241135646 BUSINESS ADDRESS: STREET 1: 11 APEX DRIVE, SUITE 300A STREET 2: PMB 2006 CITY: MARLBOROUGH STATE: MA ZIP: 01752 BUSINESS PHONE: (508) 767-3861 MAIL ADDRESS: STREET 1: 11 APEX DRIVE, SUITE 300A STREET 2: PMB 2006 CITY: MARLBOROUGH STATE: MA ZIP: 01752 FORMER COMPANY: FORMER CONFORMED NAME: RXi Pharmaceuticals Corp DATE OF NAME CHANGE: 20111019 D 1 primary_doc.xml X0708 D LIVE 0001533040 Phio Pharmaceuticals Corp. 11 Apex Drive Suite 300A, PMB 2006 Marlborough MA MASSACHUSETTS 01752 508-767-3861 DELAWARE RXi Pharmaceuticals Corporation RXi Pharmaceuticals Corp Corporation true Robert J. Bitterman 11 Apex Drive Suite 300A, PMB 2006 Marlborough MA MASSACHUSETTS 01752 Director Executive Officer Patricia A. Bradford 11 Apex Drive Suite 300A, PMB 2006 Marlborough MA MASSACHUSETTS 01752 Director Robert L. Ferrara 11 Apex Drive Suite 300A, PMB 2006 Marlborough MA MASSACHUSETTS 01752 Director Jonathan E. Freeman 11 Apex Drive Suite 300A, PMB 2006 Marlborough MA MASSACHUSETTS 01752 Director Curtis A. Lockshin, Ph.D. 11 Apex Drive Suite 300A, PMB 2006 Marlborough MA MASSACHUSETTS 01752 Director Biotechnology Decline to Disclose 06b false 2024-07-11 false true true false 0 H.C. Wainwright & Co., LLC 375 None None 430 Park Avenue 3rd Floor New York NY NEW YORK 10022 IL ILLINOIS NY NEW YORK TX TEXAS 6358543 136322 6222221 The offering amount reflects the aggregate purchase price received and exercise price due to the Company assuming cash exercise of all warrants issued to the accredited investors and placement agent in the private placement under Rule 506(b). false 8 349191 0 In connection with the offering, the placement agent received $379,191 and warrants to purchase up to 40,896 shares of common stock exercisable at $6.8125 per share. 0 Phio Pharmaceuticals Corp. /s/ Robert J. Bitterman Robert J. Bitterman President and Chief Executive Officer 2024-07-23